APA (7th ed.) Citation

JH, J., SO, K., SC, M., EG, K., MS, S., & EY, S. (2025). Regorafenib as a potential drug for severe COVID-19: Inhibition of inflammasome activation in mice. FEBS open bio, 15(3), 427. https://doi.org/10.1002/2211-5463.70002

Chicago Style (17th ed.) Citation

JH, Jeong, Kim SO, Min SC, Kim EG, Song MS, and Shin EY. "Regorafenib as a Potential Drug for Severe COVID-19: Inhibition of Inflammasome Activation in Mice." FEBS Open Bio 15, no. 3 (2025): 427. https://doi.org/10.1002/2211-5463.70002.

MLA (9th ed.) Citation

JH, Jeong, et al. "Regorafenib as a Potential Drug for Severe COVID-19: Inhibition of Inflammasome Activation in Mice." FEBS Open Bio, vol. 15, no. 3, 2025, p. 427, https://doi.org/10.1002/2211-5463.70002.